Immutep Ltd IMMP

Healthcare Biotechnology

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in ...

NDAQ:IMMP - Post by User

Immutep Ltd

Bullboard Posts

(217)
•••

Post by coolfooldumbguyon Jul 15, 2024 7:41pm

47 Views

Post# 36133836

It was a buy for me today,play it again Sam.

I played this one about 5 years ago,and it was time for me to do it again,for it should be a nice triple your money for me with this one,using my charts,so glta with it.

Bullboard Posts

Bombardier taps new leaders for strategy, defence and sales